We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
CTI Announces Data Presentations at the 55th ASH Annual Meeting
News

CTI Announces Data Presentations at the 55th ASH Annual Meeting

CTI Announces Data Presentations at the 55th ASH Annual Meeting
News

CTI Announces Data Presentations at the 55th ASH Annual Meeting

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "CTI Announces Data Presentations at the 55th ASH Annual Meeting"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cell Therapeutics, Inc. (CTI) has announced the upcoming presentations of data highlighting pacritinib, a novel, oral JAK2/FLT3 inhibitor, and tosedostat, an aminopeptidase inhibitor, at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 7-10, 2013 in New Orleans, LA.

The presentations will include data from additional analyses of completed Phase 2 trials of pacritinib in patients with myelofibrosis and data from investigator-sponsored clinical trials of tosedostat for first line acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) and a separate study in relapsed patients.

A summary of the presentations is below, and full abstracts can be accessed on the ASH website at www.hematology.org.

Oral Presentation

Pacritinib, a Dual JAK2/FLT3 Inhibitor: An Integrated Efficacy and Safety Analysis of Phase II Trial Data in Patients with Primary and Secondary Myelofibrosis (MF) and Platelet Counts ≤ 100,000 µL

• First Author: Dr. Srdan Verstovsek, MD Anderson Cancer Center, Houston, TX
• Date/Time: Monday, December 9, 2013 at 11:30 a.m. CT
• Location: Theater C
• Oral Session: 634, Myeloproliferative Syndromes: Clinical I
• Abstract #395

Poster Presentations

A Phase I/II Study of Cytarabine or Azacitidine in Combination with Tosedostat in Older Patients with AML or High-Risk MDS

• First Author: Dr. Courtney DiNardo, MD Anderson Cancer Center, Houston, TX
• Date/Time: Sunday, December 8, 2013, 6:30-8:30 p.m. CT
• Location: Hall E
• Poster Presentation: 615, Acute Myeloid Leukemia: Therapy, excluding Transplantation: Poster II
• Abstract #2698

A Phase II Study of Tosedostat (TST) in Combination with Either Cytarabine or Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

• First Author: Dr. Raya Mawad, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA
• Date/Time: Monday, December 9, 2013, 6:00-8:00 p.m. CT
• Location: Hall E
• Poster Presentation: 615, Acute Myeloid Leukemia: Therapy, excluding Transplantation: Poster III
• Abstract #3926

Exposure-Response Analysis for Pacritinib (SB1518), a Novel Oral JAK2/FLT3 Inhibitor, In Patients With Myelofibrosis

• First Author: Dr. Suliman Al-Fayoumi, Cell Therapeutics, Inc., Seattle, WA
• Date/Time: Monday, December 9, 2013 at 6:00-8:00 p.m. CT
• Location: Hall E
• Poster Presentation: 634, Myeloproliferative Syndromes: Clinical: Poster III
• Abstract #4080

Advertisement